South Africa's Aspen finalizes GSK deal for $263 million
JOHANNESBURG (Reuters) - South Africa's Aspen Pharmacare (APNJ.J) said on Monday it has finalized the acquisition of medicines from GlaxoSmithKline (GSK.L) for 163.8 million pounds ($263 million).
The deal, announced in August, was initially pegged at 172 million pounds.
($1 = 0.6240 British pounds)
(Reporting by Olivia Kumwenda; editing by David Dolan)